Pressure Biosciences (PBIO) 0.3080 $PBIO
Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems
PR Newswire - Fri Sep 19, 8:55AM CDT
Biotech companies make announcements illustrating significant progress in medical technology, development of emerging drug systems and advanced Laboratory Instrumentation. Companies in focus today are: (OTC: PBIO), Benton, Dickinson and Company (NYSE: BDX), Thermo Fisher Scientific Inc. (NYSE: TMO), Regado Biosciences Inc. (NASDAQ: RGDO), Sangamo Biosciences Inc. (NASDAQ: SGMO) and Hologic Inc. (NASDAQ: HOLX)
Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System
PR Newswire - Fri Sep 19, 7:31AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
today announced it has received and approved all parts required to build nine high throughput Barozyme HT48 instruments and has begun to manufacture the new PCT-based instrument system. The Company believes the first instrument will be ready for shipment by mid-October and that additional Barozyme instruments will be built and released at a rate of about one per week thereafter.
Steady Growth and Cutting-Edge Technologies Are Trademarks of Pressure BioSciences, Inc. (PBIO)
ACCESSWIRE - Mon Sep 15, 7:45AM CDT
Boca Raton, FL / ACCESSWIRE / September 15, 2014 / Thanks to a combination of market ingenuity and a strong scientific core, life science stalwart Pressure BioSciences (OTCQB
BIO) continues to enjoy a resurgence of relevance as a veteran company. PBIO's patented "pressure cycling technology, "or PCT", is an up-and-coming, exciting, critically acclaimed resource for scientific sample preparation by its unique ability to offer unparalleled control of the actions of molecular cell and tissue samples through an intense pressure system. This process is used in applications as diverse as forensics, bio-marker discovery, and vaccine development.
Pressure BioSciences, Inc. to Present at Rodman & Renshaw and SeeThruEquity NY Investment Conferences
PR Newswire - Wed Sep 10, 9:56AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview and business update at the Rodman and Renshaw ("Rodman" and SeeThruEquity ("STE" Investment Conferences this week in New York City. Mr. Schumacher's presentation at Rodman is scheduled for Wednesday, September 10 at 12:05pm in the Palace Hotel. Mr. Schumacher's presentation at STE is scheduled for Thursday, September 11 at 9:00am at the Convene Times Square.
Pressure BioSciences Inc. ("PBI" (OTCQB: PBIO) Exclusive Interview for Interlinked's Investment News Channel, InterlinkedTV at FSXinterlinked Investment Conference
PRWeb - Thu Aug 28, 5:02AM CDT
Pressure BioSciences Inc., ("PBI" (OTCQB: PBIO) was one of the presenting companies at the recent FSXinterlinked Investment Conference held at the Four Seasons Hotel in Westlake Village, California.
Pressure BioSciences, Inc. ("PBI" (OTCQB: PBIO) to Discuss Second Quarter 2014 Financial Results and Provide a Business Update
PRWeb - Wed Aug 13, 6:05PM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company" today announced that the Company will host a teleconference to discuss its Second Quarter 2014 financial results and to provide a business update. Anyone interested may listen to the teleconference either by telephone (live) or through a replay by telephone or on the Company's website.
Pressure BioSciences Inc. to Host Second Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, August 14, 2014
ACCESSWIRE - Wed Aug 13, 3:06PM CDT
SOUTH EASTON, MA / ACCESSWIRE / August 13, 2014 / Pressure BioSciences Inc. (OTCQB: PBIO) will host a conference call and live webcast to discuss the results of the second quarter 2014, to be held Thursday, August 14, 2014 at 4:30 PM Eastern Time.
Pressure BioSciences, Inc. to Discuss Second Quarter 2014 Financial Results and Provide a Business Update
PR Newswire - Wed Aug 13, 7:23AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company" today announced that the Company will host a teleconference to discuss its Second Quarter 2014 financial results and to provide a business update. Anyone interested may listen to the teleconference either by telephone (live) or through a replay by telephone or on the Company's website.
Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform
PR Newswire - Tue Jul 22, 6:11AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" and Parabase Genomics ("Parabase" , (together "the companies" , today announced they have entered into a strategic research and development agreement (the "collaboration" . Under the terms of the collaboration, PBI will develop a front-end, sample preparation method for Parabase's enhanced neonatal molecular diagnostics and newborn confirmatory testing process. The sample preparation method will be based on PBI's patented and enabling Pressure Cycling Technology ("PCT" platform.
Pressure BioSciences, Inc. (OTCQB: PBIO) to Present at the FSXinterlinked Investment Conference
PRWeb - Tue Jul 15, 6:08AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview and business update at the FSXinterlinked Investment Conference being held from July 30th to August 2nd, 2014 at the Four Seasons, Westlake Village, CA.
Pressure BioSciences Engages IssuWorks in Strategic Advisory Role
PR Newswire - Thu Jun 26, 8:53AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" today announced the engagement of IssuWorks to provide strategic advisory services to the Company's board of directors and management team. IssuWorks is the first conflict-free, company-aligned investment bank using technology and services to dramatically improve investor targeting, securities marketing, and distribution in public and private markets. Pressure BioSciences has retained IssuWorks and their management team to review strategic and financing alternatives, including the possible spin-off of vertical market applications into new, stand alone businesses.
Launch of Novel, High Throughput PCT-based Barozyme HT48 System "Very Successful" Says Pressure BioSciences
PR Newswire - Mon Jun 23, 7:16AM CDT
On June 12, 2014, Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" announced the planned launch of their much anticipated, high throughput pressure cycling technology ("PCT" -based system at the 62nd conference of the American Society for Mass Spectrometry ("ASMS" . The ASMS Conference was held June 15-19, 2014 in Baltimore, MD.
Transformative Impact and Adoption of Pressure BioSciences' PCT Platform Prominently Highlighted Throughout Week at Major Scientific Conference
PR Newswire - Thu Jun 19, 10:46AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" today announced that scientists from six separate research groups presented data at the 62nd Annual Conference of the American Society for Mass Spectrometry ("ASMS" being held from June 15-19, 2014 in Baltimore, MD. Study results indicated that utilizing the Company's patented pressure cycling technology ("PCT" platform in the preparation of samples for analysis resulted in critically enabling quality and/or improved time or cost efficiency of test results. These studies were conducted by scientists from ETH Zurich and the University of Zurich ("ETH Zurich" ; Laboratory Corporation of America ("Lab Corp" ; the Food and Drug Administration ("FDA" ; the University of Minnesota ("UMN" , Mayo Clinic, and the Karolinska Instituet; Northeastern University ("NEU" ; and the Baltimore VA Medical Center ("BVAMC" , SAIC-Frederick, National Cancer Institute, and the Veteran's Health Administration.
Pressure BioSciences to Launch Its Much Anticipated High Throughput PCT-based Instrument System (the Barozyme HT48) at the Upcoming ASMS Annual Conference
PR Newswire - Thu Jun 12, 11:43AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" today announced it will launch its high throughput, PCT-based Barozyme HT48 instrument system for the enhanced preparation of proteins for mass spectrometry analysis at the upcoming American Society for Mass Spectrometry ("ASMS" Annual Conference on Mass Spectrometry and Allied Topics. The ASMS Conference is being held June 15-19, 2014 in Baltimore, Maryland.
Pressure BioSciences, Inc. Reports Strong Fourth Quarter and Fiscal Year 2013 Financial Results
PR Newswire - Tue Apr 01, 9:42AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" today announced financial results for the three-month period and fiscal year ended December 31, 2013 and provided a business update.
Pressure BioSciences, Inc. to Discuss Fourth Quarter and Fiscal Year 2013 Financial Results and Provide a Business Update
PR Newswire - Mon Mar 31, 8:37AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company" today announced that the Company will host a teleconference to discuss its Fourth Quarter and Fiscal Year 2013 financial results and to provide a business update. Anyone interested may listen to the teleconference either by telephone (live) or through a replay on the Company's website. The teleconference information is provided below:
Pressure BioSciences Inc. Exclusive Interview for the Interlinked Investment News Channel on InterlinkedTV
PRWeb - Fri Mar 21, 3:37PM CDT
Pressure BioSciences Inc. was one of the presenting companies interviewed at the recent FSXinterlinked Investment Conference, held at the Ritz Carlton in Dallas, Texas.
Pressure BioSciences Announces the Release and Initial Sale of the Barocycler HUB880, a "First-in-Kind" Ultra High Pressure Bench-top Instrument System
PR Newswire - Wed Mar 19, 9:23AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" today announced the commercial release of the Barocycler HUB880, the newest addition to the Company's growing line of high-pressure instrument systems. The Company also announced the sale (and shipment) of its first HUB880 system to Dr. Wayne Hubbell of the University of California Los Angeles (UCLA). PBI plans to showcase the HUB880 at the upcoming U.S. Human Proteome Organization's 10th Annual Conference to be held at the Westin-Seattle (WA), April 6-9, 2014.
Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems
PR Newswire - Fri Sep 19, 8:55AM CDT
Biotech companies make announcements illustrating significant progress in medical technology, development of emerging drug systems and advanced Laboratory Instrumentation. Companies in focus today are: (OTC: PBIO), Benton, Dickinson and Company (NYSE: BDX), Thermo Fisher Scientific Inc. (NYSE: TMO), Regado Biosciences Inc. (NASDAQ: RGDO), Sangamo Biosciences Inc. (NASDAQ: SGMO) and Hologic Inc. (NASDAQ: HOLX)
Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System
PR Newswire - Fri Sep 19, 7:31AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
today announced it has received and approved all parts required to build nine high throughput Barozyme HT48 instruments and has begun to manufacture the new PCT-based instrument system. The Company believes the first instrument will be ready for shipment by mid-October and that additional Barozyme instruments will be built and released at a rate of about one per week thereafter. Steady Growth and Cutting-Edge Technologies Are Trademarks of Pressure BioSciences, Inc. (PBIO)
ACCESSWIRE - Mon Sep 15, 7:45AM CDT
Boca Raton, FL / ACCESSWIRE / September 15, 2014 / Thanks to a combination of market ingenuity and a strong scientific core, life science stalwart Pressure BioSciences (OTCQB
BIO) continues to enjoy a resurgence of relevance as a veteran company. PBIO's patented "pressure cycling technology, "or PCT", is an up-and-coming, exciting, critically acclaimed resource for scientific sample preparation by its unique ability to offer unparalleled control of the actions of molecular cell and tissue samples through an intense pressure system. This process is used in applications as diverse as forensics, bio-marker discovery, and vaccine development. Pressure BioSciences, Inc. to Present at Rodman & Renshaw and SeeThruEquity NY Investment Conferences
PR Newswire - Wed Sep 10, 9:56AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview and business update at the Rodman and Renshaw ("Rodman" and SeeThruEquity ("STE" Investment Conferences this week in New York City. Mr. Schumacher's presentation at Rodman is scheduled for Wednesday, September 10 at 12:05pm in the Palace Hotel. Mr. Schumacher's presentation at STE is scheduled for Thursday, September 11 at 9:00am at the Convene Times Square. Pressure BioSciences Inc. ("PBI"
(OTCQB: PBIO) Exclusive Interview for Interlinked's Investment News Channel, InterlinkedTV at FSXinterlinked Investment Conference PRWeb - Thu Aug 28, 5:02AM CDT
Pressure BioSciences Inc., ("PBI"
(OTCQB: PBIO) was one of the presenting companies at the recent FSXinterlinked Investment Conference held at the Four Seasons Hotel in Westlake Village, California. Pressure BioSciences, Inc. ("PBI"
(OTCQB: PBIO) to Discuss Second Quarter 2014 Financial Results and Provide a Business Update PRWeb - Wed Aug 13, 6:05PM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"
today announced that the Company will host a teleconference to discuss its Second Quarter 2014 financial results and to provide a business update. Anyone interested may listen to the teleconference either by telephone (live) or through a replay by telephone or on the Company's website. Pressure BioSciences Inc. to Host Second Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, August 14, 2014
ACCESSWIRE - Wed Aug 13, 3:06PM CDT
SOUTH EASTON, MA / ACCESSWIRE / August 13, 2014 / Pressure BioSciences Inc. (OTCQB: PBIO) will host a conference call and live webcast to discuss the results of the second quarter 2014, to be held Thursday, August 14, 2014 at 4:30 PM Eastern Time.
Pressure BioSciences, Inc. to Discuss Second Quarter 2014 Financial Results and Provide a Business Update
PR Newswire - Wed Aug 13, 7:23AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"
today announced that the Company will host a teleconference to discuss its Second Quarter 2014 financial results and to provide a business update. Anyone interested may listen to the teleconference either by telephone (live) or through a replay by telephone or on the Company's website. Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform
PR Newswire - Tue Jul 22, 6:11AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
and Parabase Genomics ("Parabase" , (together "the companies" , today announced they have entered into a strategic research and development agreement (the "collaboration" . Under the terms of the collaboration, PBI will develop a front-end, sample preparation method for Parabase's enhanced neonatal molecular diagnostics and newborn confirmatory testing process. The sample preparation method will be based on PBI's patented and enabling Pressure Cycling Technology ("PCT" platform. Pressure BioSciences, Inc. (OTCQB: PBIO) to Present at the FSXinterlinked Investment Conference
PRWeb - Tue Jul 15, 6:08AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview and business update at the FSXinterlinked Investment Conference being held from July 30th to August 2nd, 2014 at the Four Seasons, Westlake Village, CA. Pressure BioSciences Engages IssuWorks in Strategic Advisory Role
PR Newswire - Thu Jun 26, 8:53AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
today announced the engagement of IssuWorks to provide strategic advisory services to the Company's board of directors and management team. IssuWorks is the first conflict-free, company-aligned investment bank using technology and services to dramatically improve investor targeting, securities marketing, and distribution in public and private markets. Pressure BioSciences has retained IssuWorks and their management team to review strategic and financing alternatives, including the possible spin-off of vertical market applications into new, stand alone businesses. Launch of Novel, High Throughput PCT-based Barozyme HT48 System "Very Successful" Says Pressure BioSciences
PR Newswire - Mon Jun 23, 7:16AM CDT
On June 12, 2014, Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
announced the planned launch of their much anticipated, high throughput pressure cycling technology ("PCT" -based system at the 62nd conference of the American Society for Mass Spectrometry ("ASMS" . The ASMS Conference was held June 15-19, 2014 in Baltimore, MD. Transformative Impact and Adoption of Pressure BioSciences' PCT Platform Prominently Highlighted Throughout Week at Major Scientific Conference
PR Newswire - Thu Jun 19, 10:46AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
today announced that scientists from six separate research groups presented data at the 62nd Annual Conference of the American Society for Mass Spectrometry ("ASMS" being held from June 15-19, 2014 in Baltimore, MD. Study results indicated that utilizing the Company's patented pressure cycling technology ("PCT" platform in the preparation of samples for analysis resulted in critically enabling quality and/or improved time or cost efficiency of test results. These studies were conducted by scientists from ETH Zurich and the University of Zurich ("ETH Zurich" ; Laboratory Corporation of America ("Lab Corp" ; the Food and Drug Administration ("FDA" ; the University of Minnesota ("UMN" , Mayo Clinic, and the Karolinska Instituet; Northeastern University ("NEU" ; and the Baltimore VA Medical Center ("BVAMC" , SAIC-Frederick, National Cancer Institute, and the Veteran's Health Administration. Pressure BioSciences to Launch Its Much Anticipated High Throughput PCT-based Instrument System (the Barozyme HT48) at the Upcoming ASMS Annual Conference
PR Newswire - Thu Jun 12, 11:43AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
today announced it will launch its high throughput, PCT-based Barozyme HT48 instrument system for the enhanced preparation of proteins for mass spectrometry analysis at the upcoming American Society for Mass Spectrometry ("ASMS" Annual Conference on Mass Spectrometry and Allied Topics. The ASMS Conference is being held June 15-19, 2014 in Baltimore, Maryland. Pressure BioSciences, Inc. Reports Strong Fourth Quarter and Fiscal Year 2013 Financial Results
PR Newswire - Tue Apr 01, 9:42AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
today announced financial results for the three-month period and fiscal year ended December 31, 2013 and provided a business update. Pressure BioSciences, Inc. to Discuss Fourth Quarter and Fiscal Year 2013 Financial Results and Provide a Business Update
PR Newswire - Mon Mar 31, 8:37AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"
today announced that the Company will host a teleconference to discuss its Fourth Quarter and Fiscal Year 2013 financial results and to provide a business update. Anyone interested may listen to the teleconference either by telephone (live) or through a replay on the Company's website. The teleconference information is provided below: Pressure BioSciences Inc. Exclusive Interview for the Interlinked Investment News Channel on InterlinkedTV
PRWeb - Fri Mar 21, 3:37PM CDT
Pressure BioSciences Inc. was one of the presenting companies interviewed at the recent FSXinterlinked Investment Conference, held at the Ritz Carlton in Dallas, Texas.
Pressure BioSciences Announces the Release and Initial Sale of the Barocycler HUB880, a "First-in-Kind" Ultra High Pressure Bench-top Instrument System
PR Newswire - Wed Mar 19, 9:23AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
today announced the commercial release of the Barocycler HUB880, the newest addition to the Company's growing line of high-pressure instrument systems. The Company also announced the sale (and shipment) of its first HUB880 system to Dr. Wayne Hubbell of the University of California Los Angeles (UCLA). PBI plans to showcase the HUB880 at the upcoming U.S. Human Proteome Organization's 10th Annual Conference to be held at the Westin-Seattle (WA), April 6-9, 2014. 
